Introduction: Ceftriaxone, a third-generation cephalosporin, is frequently used for the treatment of various bacterial infections as a broad-spectrum antibiotic for many decades. Although ceftriaxone is a well-tolerated drug in most cases, it can lead to serious liver injury, which can be a real challenge to the treating physician. Given the potentially serious adverse effects that can vary from mild biochemical abnormalities to complete liver failure, we intend to assess the spectrum of liver injury based on biochemical criteria for patients treated with ceftriaxone for common bacterial infections in Qatar.Objectives: This study aimed to explore the incidence of ceftriaxone-induced liver injury at Hazm Mebaireek General Hospital, Qatar, and to evaluate the relationship of the ceftriaxone dose, if any, with liver dysfunction.Methods: This retrospective study included hospitalized adult patients treated with ceftriaxone at our hospital from January 2019 to December 2019 and analyzed demographic and clinical data obtained from electronic medical records. This study determined the incidence of liver injury (primary outcome) in patients treated with ceftriaxone (2 g/day) for ≥ 2 consecutive days by reviewing liver function test results until the day of discharge and at the first outpatient follow-up. Results: The final data analysis included a total of 634 patients admitted and treated with ceftriaxone from January 2019 to December 2019.In the multivariate analysis with propensity score adjustment, ceftriaxone was independently associated with liver injury, especially when combined with other agents utilizing hepatic metabolism.Conclusions: Ceftriaxone was associated with a significantly higher incidence of liver injury (19.7%) when used along with other medications that are metabolized in the liver, as found in the present study compared with other similar studies (approximately 2.9%–13.9%). Furthermore, the incidence was too high to be ignored in clinical practice.

Purpose We aimed to determine the incidence of venous thromboembolism among hospitalized patients in Qatar as well as to analyze the adequacy of VTE assessment and prophylaxis in hospitalized patients. Design Retrospective observational study. Setting Four hospitals under Hamad Medical Corporation, Qatar. Participants Patients over the age of 18 who were hospitalized between January 2015 and December 2019 and developed venous thromboembolism during hospitalization or within a month after discharge were included. Results During the study period, 641,994 individuals were admitted to hospitals. The inclusion criteria were satisfied by 209 of them. The mean age was 51.25 years and 54.5% were males. Hypertension and diabetes mellitus were the most common comorbidities found in the overall group. The incidence of VTE was 32.55 [95% CI 28.4, 37.3] per 100,000 admission per year [0.032%]. The annual incidence was least in 2015 (17.8 per 100,000 admissions) and highest in 2018 (44.4 per 100,000 admissions). Eighty-six subjects had DVT, and 109 had PE, whereas 14 had both. And, 67.5% of the patients developed VTE during admission while, 32.5% developed within 1 month of discharge. Moreover, 22.9% of the patients with PE developed pulmonary embolism after discharge from the hospital. VTE assessment was performed on 64.7% of the patients, and 69.7% received VTE prophylaxis in accordance with guidelines. Conclusion Although the occurrence of VTE among hospitalized patients in Qatar is low, healthcare providers need additional education and knowledge of VTE assessment and prophylaxis to follow guidelines for all patients at the time of admission. Furthermore, risk assessment for VTE should be done for all patients at the time of discharge to decide on post-discharge prophylaxis so that incidence of VTE after discharge can be minimized. Future studies should focus on patients who developed VTE after discharge from the hospital as well as on various risk factors.

Brucellosis is one of the world's most prevalent zoonotic illnesses. The most often afflicted joints are the sacroiliac joints, although spondylitis and peripheral arthritis are becoming increasingly prevalent. We described a case of a 40‐year‐old male patient with Brucellosis presented as septic knee arthritis.

Introduction: Remdesivir is an antiviral medication approved by the US Food and Drug Administration to combat COVID-19 infection in hospitalized patients. Although the adverse effects of Remdesivir are mainly unknown, data from randomized controlled trials have demonstrated its deleterious impact on several organ systems. Purpose: This study aims to describe the safety and efficacy of Remdesivir administration in a cohort of 586 patients admitted to a tertiary hospital in Qatar for COVID-19-related reasons. Methods: A retrospective study of 586 patients admitted with a diagnosis of COVID-19 and treated with Remdesivir were compared to 200 patients with COVID-19 who did not receive Remdesivir. Results: The rate of mechanical ventilation admission to the intensive care unit was comparable across the two groups (2.35% vs. 2%, p =.75). Death rates were comparable between the two groups (0.02% vs. 0.03%, p =.43). There was a mean reduction in heart rate within the first three days of antiviral therapy. Negligible variations in serum AST, ALT, ALP, and eGFR levels were detected. Remdesivir-treated patients had a significantly shorter hospital stay. Conclusion: Based on the limited data available regarding the adverse effects of Remdesivir, it is prudent to exercise caution by evaluating baseline parameters and avoiding concomitant use of potential cardio-, nephro-, or hepatotoxic drugs when using Remdesivir in patients hospitalized with COVID-19.